Case Series on Iris Depigmentation and Transillumination
Author Information
Author(s): Flavia Veiga Costa, Amanda Gomes e Silva, Leticia Alcântara Pedroso, Ana Luiza Biancardi, André Luiz Curi
Primary Institution: Instituto Nacional de Infectologia, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil
Hypothesis
Can moxifloxacin use trigger iris depigmentation and transillumination in patients?
Conclusion
The study suggests that moxifloxacin may trigger iris depigmentation and transillumination, particularly in patients with recent COVID-19.
Supporting Evidence
- All five patients experienced acute onset of bilateral pain and redness of the eyes after moxifloxacin use.
- Four patients used oral moxifloxacin, while one used it topically.
- Three patients had elevated intraocular pressure during their first visit.
Takeaway
This study looked at five women who had eye problems after using a medicine called moxifloxacin, which might be linked to their symptoms.
Methodology
The study involved a retrospective review of medical records from a tertiary uveitis center, focusing on patients diagnosed with BADI or BAIT.
Limitations
The study is limited by its small sample size and retrospective design.
Participant Demographics
All participants were female with a mean age of 41 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website